ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
-
Credit Suisse Healthcare Conference November 13 at4:00pm MST (6:00pm EST ),Scottsdale, AZ -
Jefferies 2013 Global Healthcare Conference
November 21 at1:40 pm GMT (8:40am EST ),London, England -
Oppenheimer 24th Annual Conference
December 11 at1:00 pm EST ,New York, NY
The webcasts will be accessible live through the "Investor Information" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.
About
ImmunoGen develops targeted anticancer compounds with its well-tested
ADC technology, which uses a tumor-targeting antibody to deliver one of
the Company's proprietary cancer-cell killing agents specifically to
tumor cells. The most advanced compound with ImmunoGen's ADC technology
is Roche's Kadcyla®, which is marketed in the US by
Kadcyla® is a registered trademark of
For Investors:
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Source:
News Provided by Acquire Media